Shi Hui-Juan, Song Hongbin, Zhao Qian-Ying, Tao Chun-Xia, Liu Min, Zhu Qin-Qin
Department of Dermatovenereology, Ningxia Medical University General Hospital, Yinchuan Department of Dermatology, Chinese PLA General Hospital, Beijing Medical Experimental Center, Ningxia Medical University General Hospital Department of Dermatovenereology, Ningxia Yangguang Hospital, Yinchuan, China.
Medicine (Baltimore). 2018 Sep;97(37):e12398. doi: 10.1097/MD.0000000000012398.
We evaluated the efficacy and safety of combined high-dose interferon (IFN) and red light therapy for the treatment of subclinical and latent human papillomavirus (HPV) infections.
Ninety women diagnosed with subclinical or latent HPV infection were randomized to receive topical application of low-dose recombinant IFNα-2b (1 million IU), high-dose IFNα-2b (9 million IU), or a combination of high-dose IFNα-2b and red light therapy on the cervix and vagina. All patients received treatment once daily for 4 weeks. HPV titer was measured immediately and 4, 8, and 12 weeks after treatment to determine the rates of viral clearance and infection cure. Treatment of HPV-associated vaginitis and cervicitis was also evaluated.
Results showed that immediately and 4, 8, and 12 weeks after treatment, the HPV clearance rates and infection cure rates were higher in the high-dose IFN and combination groups compared to the low-dose IFN group. High-dose IFN and combination therapies were significantly effective against both low-risk and high-risk HPV infections. Although the cure rates for vaginitis and cervicitis were significantly higher in the high- compared to the low-dose IFN group, rates were even higher in the combination group compared to the high-dose IFN group. Mild adverse effects were reported by a very small subset of patients (3/30) in the combination group.
This study suggests that combination of high-dose IFN and red light therapy is safe and effective against subclinical and latent HPV infections.
我们评估了大剂量干扰素（IFN）联合红光疗法治疗亚临床和潜伏性人乳头瘤病毒（HPV）感染的疗效和安全性。
90名被诊断为亚临床或潜伏性HPV感染的女性被随机分为三组，分别接受宫颈和阴道局部应用低剂量重组IFNα-2b（100万国际单位）、高剂量IFNα-2b（900万国际单位）或高剂量IFNα-2b与红光疗法联合治疗。所有患者每天治疗1次，共4周。在治疗前、治疗后4周、8周和12周测量HPV滴度，以确定病毒清除率和感染治愈率。同时评估HPV相关性阴道炎和宫颈炎的治疗情况。
结果显示，在治疗后即刻、4周、8周和12周，高剂量IFN组和联合治疗组的HPV清除率和感染治愈率均高于低剂量IFN组。高剂量IFN和联合治疗对低危和高危HPV感染均有显著疗效。虽然高剂量IFN组阴道炎和宫颈炎的治愈率显著高于低剂量IFN组，但联合治疗组的治愈率高于高剂量IFN组。联合治疗组中极少数患者（3/30）报告有轻度不良反应。
本研究表明，高剂量IFN联合红光疗法治疗亚临床和潜伏性HPV感染安全有效。
